文献速递血液净化与透析肾移植

癌症合并肾衰竭患者的相对生存研究

Relative survival in patients with cancer and kidney failure.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该研究评估了1980-2019年澳大利亚和新西兰透析及肾移植受者中新发癌症患者的相对生存,并与普通癌症人群比较。透析患者5年相对生存率仅0.25,肾移植受者为0.55,均显著低于普通癌症人群;超额死亡率分别高出2.16倍和1.34倍。

要点

  • 透析患者癌症5年相对生存率0.25,移植受者0.55,均远低于普通癌症人群
  • 透析和移植受者癌症超额死亡率分别高出普通癌症人群2.16倍和1.34倍
  • 黑色素瘤、乳腺癌和前列腺癌的生存缺陷在肾衰竭人群中尤为显著

核心结论

  • 肾衰竭合并癌症患者的相对生存显著低于普通癌症人群,透析者尤为突出。
  • 肺癌超额死亡率与普通癌症人群无差异,但黑色素瘤、乳腺癌和前列腺癌存在显著生存缺陷。

研究设计与样本

  • 基于澳大利亚和新西兰1980-2019年数据的相对生存分析。
  • 以全人群为背景死亡率参照,按性别、年龄、日历年和国家调整,采用泊松回归量化超额死亡比。

主要发现

  • 全部位癌症5年相对生存:透析0.25(95%CI 0.23-0.26),肾移植0.55(95%CI 0.53-0.57)。
  • 超额死亡比:透析2.16(95%CI 2.08-2.25),肾移植1.34(95%CI 1.27-2.41)。
  • 肺癌超额死亡与普通癌症人群无差异;黑色素瘤、乳腺癌和前列腺癌生存缺陷显著。

临床怎么用

  • 肾衰竭患者癌症生存差,需关注多病共存、治疗可及性及治疗毒性或疗效差异。
  • 对黑色素瘤、乳腺癌和前列腺癌应加强筛查和个体化治疗评估。

局限性

  • 观察性设计可能受多病负担、治疗可及性等混杂因素影响。
  • 原文未报告具体治疗暴露和合并症调整细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The population with kidney failure is at increased risk of cancer and associated mortality. Relative survival can provide insight into the excess mortality, directly or indirectly, attributed to cancer in the population with kidney failure. METHODS: We estimated relative survival for people all ages receiving dialysis (n = 4089) and kidney transplant recipients (n = 3253) with de novo cancer, and for the general population with cancer in Australia and New Zealand (n = 3 043 166) over the years 1980-2019. The entire general population was the reference group for background mortality, adjusted for sex, age, calendar year and country. We used Poisson regression to quantify excess mortality ratios. RESULTS: Five-year relative survival for all-site cancer was markedly lower than that for the general population for people receiving dialysis [0.25, 95% confidence interval (CI) 0.23-0.26] and kidney transplant recipients (0.55, 95% CI 0.53-0.57). In dialysis, excess mortality was more than double (2.16, 95% CI 2.08-2.25) that of the general population with cancer and for kidney transplant recipients 1.34 times higher (95% CI 1.27-2.41). There was no difference in excess mortality from lung cancer between people with kidney failure and the general population with cancer. Comparatively, there was a significant survival deficit for people with kidney failure, compared with the general population with cancer, for melanoma, breast cancer and prostate cancers. CONCLUSION: Decreased cancer survival in kidney failure may reflect differences in multi-morbidity burden, reduced access to treatment, or greater harm from or reduced efficacy of treatments. Our findings support research aimed at investigating these hypotheses.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Oliveras L, Rosales BM, De La Mata N, et al. Relative survival in patients with cancer and kidney failure. Nephrol Dial Transplant. 2024. PMID: 38383906. doi:10.1093/ndt/gfae046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。